Evidence map›Paper›PMID 28915604›Full record

ArticleOncotarget2017

Overexpression of a functional calcium-sensing receptor dramatically increases osteolytic potential of MDA-MB-231 cells in a mouse model of bone metastasis through epiregulin-mediated osteoprotegerin downregulation.

Cédric Boudot, Lucie Hénaut, Ursula Thiem, Sandra Geraci, Mariangela Galante, Paulo Saldanha, Zuzana Saidak, Isabelle Six, Philippe Clézardin, Said Kamel and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. Calcium-Sensing Receptor Expression in Breast Cancer.International journal of molecular sciences · 2023
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. The RANK-RANKL axis: an opportunity for drug repurposing in cancer?Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019
    Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Cédric Boudot *Inserm U1088, Centre Universitaire de Recherche en Santé, Université de Picardie Jules Verne, Amiens, France.
Lucie Hénaut *Inserm U1088, Centre Universitaire de Recherche en Santé, Université de Picardie Jules Verne, Amiens, France.
Ursula ThiemInserm U1088, Centre Universitaire de Recherche en Santé, Université de Picardie Jules Verne, Amiens, France.
Sandra GeraciInserm UMR 1033, LYOS, Lyon, France.
Mariangela GalanteInserm U1088, Centre Universitaire de Recherche en Santé, Université de Picardie Jules Verne, Amiens, France.
Paulo SaldanhaInserm U1088, Centre Universitaire de Recherche en Santé, Université de Picardie Jules Verne, Amiens, France.
Zuzana SaidakInserm U1088, Centre Universitaire de Recherche en Santé, Université de Picardie Jules Verne, Amiens, France.
Isabelle SixInserm U1088, Centre Universitaire de Recherche en Santé, Université de Picardie Jules Verne, Amiens, France.
Philippe ClézardinInserm UMR 1033, LYOS, Lyon, France.
Said KamelInserm U1088, Centre Universitaire de Recherche en Santé, Université de Picardie Jules Verne, Amiens, France.
Romuald MentaverriInserm U1088, Centre Universitaire de Recherche en Santé, Université de Picardie Jules Verne, Amiens, France.
Inserm · FRUniversité de Picardie Jules Verne · FRPathophysiology, Diagnosis and Treatment of Bone Diseases · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

INTRODUCTION AND

aimsOsteolytic bone metastases are observed in advanced cases of breast cancer. METHODS AND

resultsMDA-MB-231 stably transfected with plasmids containing either a full-length wild-type CaSR (CaSR-WT), or a functionally inactive dominant negative mutant (CaSR-DN) or an empty vector (EV) were intratibially injected into Balb/c-Nude mice. X-ray analysis performed 19 days after injection showed a dramatic increase of osteolytic lesions in mice injected with CaSR-WT-transfected cells as compared to mice injected with EV- or CaSR-DN-transfected cells. This was associated with decreased BV/TV ratio and increased tumor burden. Epiregulin, an EGF-like ligand, was identified by a DNA microarray as a possible candidate involved in CaSR-mediated osteolysis. Indeed,

conclusionsOverexpression of a functional CaSR in metastatic breast cancer cells dramatically amplifies their osteolytic potential through epiregulin-mediated OPG downregulation.

Indexed as

bone metastasisbreast cancercalcium-sensing receptorepiregulinosteolysis

Identifiers

PMID28915604
PMCPMC5593575
OpenAlexW2606521792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.